Living With Relapsing-Remitting MS
Here is one man's journey from diagnosis and treatment to living life to the fullest with multiple sclerosis. (Source: WebMD Health)
Source: WebMD Health - April 8, 2021 Category: Consumer Health News Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Media News - April 8, 2021 Category: Pharmaceuticals Source Type: news

Monthly News Roundup - March 2021
FDA OKs Janssen’s Ponvory for Relapsing Forms of Multiple Sclerosis The U.S. Food and Drug Administration (FDA has approved Janssen’s once-daily oral Ponvory (ponesimod) tablets to treat relapsing forms of multiple sclerosis in adults,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2021 Category: Pharmaceuticals Source Type: news

Machine learning helps spot gait problems in individuals with multiple sclerosis
(University of Illinois at Urbana-Champaign, News Bureau) Monitoring the progression of multiple sclerosis-related gait issues can be challenging in adults over 50 years old, requiring a clinician to differentiate between problems related to MS and other age-related issues. To address this problem, researchers are integrating gait data and machine learning to advance the tools used to monitor and predict disease progression. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2021 Category: International Medicine & Public Health Source Type: news

A diagnosis of multiple sclerosis following whiplash injury: is there a true association? - Harris L, Hateley S, Baheerathan A, Malik O.
We report a case of a previously well, 25-year-old Caucasian female whose diagnosis of multiple sclerosis (MS) followed significant trauma. Her symptoms and signs developed quickly and  satisfied the criteria for rapidly evolving relapsing-remitting MS. Sh... (Source: SafetyLit)
Source: SafetyLit - March 27, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Usability of a fall risk mhealth app for people with multiple sclerosis: mixed methods study - Hsieh K, Fanning J, Frechette M, Sosnoff J.
BACKGROUND: Multiple sclerosis (MS) is a chronic, neurodegenerative disease that causes a range of motor, sensory, and cognitive symptoms. Due to these symptoms, people with MS are at a high risk for falls, fall-related injuries, and reductions in quality ... (Source: SafetyLit)
Source: SafetyLit - March 27, 2021 Category: International Medicine & Public Health Tags: Falls Source Type: news

FDA OKs Neuromodulation Device to Improve Gait in MS FDA OKs Neuromodulation Device to Improve Gait in MS
The Portable Neuromodulation Stimulator (PoNS) is intended for use in combination with a supervised therapeutic exercise program in patients aged 22 years and older with multiple sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 26, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Janssen Receives Positive CHMP Opinion for PONVORY ™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
BEERSE, BELGIUM, MARCH 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[3]“Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden,” said Catherine T...
Source: Johnson and Johnson - March 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UK to test existing drugs as treatment for MS in world-first trial
Researchers will test several drugs at once to speed up identification of those that slow or reverse symptomsDoctors in the UK are to launch a world-first clinical trial to assess whether drugs already on the market can prevent multiple sclerosis (MS) from worsening over time and even reverse the disabilities it causes.The groundbreaking Octopus trial, so named because of its various arms, will allow researchers to investigate the potential benefits of several drugs at once, in the hope of identifying effective new treatments three times faster than if the medicines were trialled separately.Continue reading... (Source: Gua...
Source: Guardian Unlimited Science - March 22, 2021 Category: Science Authors: Ian Sample Science editor Tags: Multiple sclerosis Science Neuroscience Medical research Society UK news Source Type: news

Driving errors that predict simulated rear-end collisions in drivers with multiple sclerosis - Krasniuk S, Classen S, Morrow SA.
OBJECTIVE: Drivers with Multiple Sclerosis (MS) may have an increased crash risk. However, the driving performance deficits that contribute to crashes are not fully understood. Based on the extant literature, adjustment to stimuli errors indicate failing a... (Source: SafetyLit)
Source: SafetyLit - March 20, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Greater Disability Tied to Worse COVID - 19 Severity in MS Patients
Risk for hospitalization, ICU admission/ventilator support, death increased in multiple sclerosis patients with ambulatory disability, older age (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 20, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Neurology, Nursing, Pulmonology, Journal, Source Type: news

FDA Approves Ponvory (ponesimod) for the Treatment of Adults with Relapsing Multiple Sclerosis
TITUSVILLE, N.J.– (March 19, 2021)– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) approved Ponvory™ (ponesimod), a once-daily oral selective... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 19, 2021 Category: Drugs & Pharmacology Source Type: news

Greater Disability Tied to Worse COVID-19 Severity in MS Patients
FRIDAY, March 19, 2021 -- Ambulatory disability and older age are associated with worse clinical severity of COVID-19, including death, among patients with multiple sclerosis (MS), according to a study published online March 19 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2021 Category: Pharmaceuticals Source Type: news

Study: COVID-19 death risk higher for people with severe MS disability
Older adults with severe disability due to multiple sclerosis are 25 times more likely to die from COVID-19 than those with more mild forms of the neurological disorder, a study published Friday by JAMA Neurology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 19, 2021 Category: Consumer Health News Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Outcomes, risk factors associated with SARS-CoV-2 infection in North American registry of patients with MS
(JAMA Network) This analysis examined how patients with multiple sclerosis who have COVID-19 fare and what patient and disease characteristics are associated with worse outcomes. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 19, 2021 Category: Infectious Diseases Source Type: news

People With MS Should Get the COVID-19 Vaccine: Expert
THURSDAY, March 18, 2021 -- People with multiple sclerosis (MS) may be wondering if they should get a COVID-19 shot, and the answer is definitely yes, an expert says. " The big takeaway message is the COVID-19 vaccine is strongly recommended for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 18, 2021 Category: General Medicine Source Type: news

UCLA forms collaboration with Yuyu Pharma to develop drug for stroke recovery
UCLA has formed a research collaboration with South Korea-based Yuyu Pharma to develop drugs that could help people recover after a stroke.Yuyu will develop drug candidates and UCLA researchers will conduct preclinical trials that could lead to further development of new compounds.Leading the research for UCLA are Istvan Mody, a distinguished professor of neurology; Varghese John, a professor of neurology and the principal investigator at theDrug Discovery Lab at UCLA; and Dr. S. Thomas Carmichael, chair of the UCLA department of neurology.There is currently no medical therapy that promotes recovery in the brain after it h...
Source: UCLA Newsroom: Health Sciences - March 16, 2021 Category: Universities & Medical Training Source Type: news

Disease Progression and Therapy Response Vary in MS by Ethnicity Disease Progression and Therapy Response Vary in MS by Ethnicity
New research shows that Black and Hispanic individuals with multiple sclerosis have more severe illness than White individuals, and that response to disease-modifying therapies varies widely.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 11, 2021 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

What gait features influence the amount and intensity of physical activity in people with multiple sclerosis? - Pau M, Porta M, Coghe G, Cocco E.
Although the mutual relationship between ambulation and physical activity (PA) in people with multiple sclerosis (pwMS) has been described in several studies, there is still a lack of detailed information about the way in which specific aspects of the gait... (Source: SafetyLit)
Source: SafetyLit - March 9, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

The impact of physical functions on depressive symptoms in people with multiple sclerosis - Tauil CB, Ramari C, DA Silva FM, Brasil E, David A, Gomes JRA, Silva FG, Brand ão CO, Dos Santos LMB, Santos-Neto LD.
BACKGROUND: Multiple sclerosis (MS) is an immune-mediated disease that affects the central nervous system. The impact of MS transcends physical functions and extends to psychological impairment. Approximately 50% of people with MS develop depressive sympto... (Source: SafetyLit)
Source: SafetyLit - March 9, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Molecule with potential to treat multiple sclerosis passes toxicology testing in zebrafish
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Study conducted at a FAPESP-supported research center shows that anti-inflammatory peptide TnP could lead to drug development. Zebrafish Danio rerio is a popular aquarium species widely used as a model for in vivo trials in drug development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Medical Marijuana Is Not Regulated as Most Medicines Are
The industry lacks randomized controlled clinical trials that can clearly establish benefits and risks. (Source: NYT Health)
Source: NYT Health - March 8, 2021 Category: Consumer Health News Authors: Jane E. Brody Tags: Medical Marijuana Cannabis Foods and Products Drug Abuse and Traffic Drugs (Pharmaceuticals) Glaucoma Multiple Sclerosis Source Type: news

Consumer Health: Treating MS
MS Awareness Week is observed March 7-13, which makes this a good time to learn more about multiple sclerosis, or MS. MS is a potentially disabling disease of the brain and spinal cord. With MS, the immune system attacks the protective sheath that covers nerve fibers, and causes communication problems between your brain and the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 8, 2021 Category: Databases & Libraries Source Type: news

Certain DMTs in MS May Attenuate COVID-19 Vaccines Certain DMTs in MS May Attenuate COVID-19 Vaccines
COVID-19 vaccines are considered safe for patients with multiple sclerosis, a neurologist told colleagues, but those who are on disease-modifying therapy, or about to begin it, should be cautious about the timing of their shots.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 5, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Erythropoietin Falls Short of Neuroprotection in Optic Neuritis Erythropoietin Falls Short of Neuroprotection in Optic Neuritis
A higher rate of conversion to multiple sclerosis in the placebo group offered a glimmer of hope for treatment in TONE, a phase 3 randomized trial, but caveats loom large.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 4, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

A multifactorial model of multiple sclerosis gait and its changes across different disability levels - Angelini L, Buckley E, Bonci T, Radford A, Sharrack B, Paling D, Nair KPS, Mazz à C.
OBJECTIVE: Mobility assessment is critical in the clinical management of people with Multiple Sclerosis (pwMS). Instrumented gait analysis provides a plethora of metrics for quantifying concurrent factors contributing to gait deterioration. However, a gait... (Source: SafetyLit)
Source: SafetyLit - March 4, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Fall prevention education for people with multiple sclerosis: a randomized clinical trial - Chanes DC, Piza FMT, San Martin G, Le ão ER, dos Santos OFP.
BACKGROUND: Online spaced education (OSE) is a method recognized for promoting long-term knowledge retention, changing behaviors, and improving outcomes for students and healthcare professionals. However, there is little evidence about the impacts on patie... (Source: SafetyLit)
Source: SafetyLit - March 4, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

AAN: Anomalously Warm Weather Tied to More MS Hospital Visits
WEDNESDAY, March 3, 2021 -- People with multiple sclerosis (MS) may expect worsening symptoms with rising average temperatures, according to a study scheduled for presentation at the upcoming annual meeting of the American Academy of Neurology, to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2021 Category: Pharmaceuticals Source Type: news

How Climate Change Could Put More MS Patients in Danger
TUESDAY, March 2, 2021 -- When temperatures rise, people with multiple sclerosis need to keep cool. Heat sensitivity is a hallmark of the central nervous system disorder. So, what happens when warm weather spikes become more frequent because of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 2, 2021 Category: General Medicine Source Type: news

MS patient sues Austria over health impact of climate change
A man in Austria with a temperature-dependent form of multiple sclerosis is taking his government to court in an effort to force it to do more against climate change (Source: ABC News: Health)
Source: ABC News: Health - March 2, 2021 Category: Consumer Health News Tags: Health Source Type: news

Opioid Use Common for Pain in Multiple Sclerosis
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 2, 2021 Category: General Medicine Source Type: news

UCLA forms research collaboration with Yuyu Pharma to advance MS treatment
Through a new collaboration with a South Korean pharmaceutical company, UCLA scientists will participate in the process to develop a new drug to treat multiple sclerosis.UCLA and Yuyu Pharma will evaluate the efficacy and safety of drugs that have the potential to treat the debilitating disease.The collaboration was facilitated by theUCLA Technology Development Group, which manages UCLA ’s intellectual property and spearheads partnerships with private industry to commercialize UCLA research.“We are excited that Yuyu Pharma chose UCLA as its first academic institution partner in the U.S.,” said Amir Naiber...
Source: UCLA Newsroom: Health Sciences - March 1, 2021 Category: Universities & Medical Training Source Type: news

Opioid Use Common for Pain in Multiple Sclerosis Opioid Use Common for Pain in Multiple Sclerosis
A study shows that 20% of MS patients report prescription opioid use. The researchers urge development of more nonpharmacologic programs.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 1, 2021 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news

NfL Levels Linked to Worse Disability in Real-World MS NfL Levels Linked to Worse Disability in Real-World MS
Greater brain atrophy and disability were observed in a real-world study of people with multiple sclerosis and elevation of serum neurofilament light chain levels.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 26, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Pediatric-Onset Multiple Sclerosis Tied to Lasting Social Consequences
WEDNESDAY, Feb. 24, 2021 -- Pediatric-onset multiple sclerosis (PoMS) is associated with less educational achievement, lower earnings, and greater use of disability benefits throughout the working-age life span, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 24, 2021 Category: Pharmaceuticals Source Type: news

JDRF, Lupus Research Alliance and National Multiple Sclerosis Society join forces to decode common m
(JDRF) JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are proud to announce the recipients of their first joint grants. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 24, 2021 Category: International Medicine & Public Health Source Type: news

Mesenchymal Stem Cell Transplantation in Progressive MS Mesenchymal Stem Cell Transplantation in Progressive MS
This study compared the the therapeutic efficacy of mesenchymal stem cell transplantation to sham treatment in patients with active or worsening progressive multiple sclerosis.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Cognitive and motor slowing mediate the relationship between depression and falls in multiple sclerosis patients - Cohen JN, Seng E, Foley FW.
OBJECTIVE: Given the limited research concerning the relationship between depression and falls in multiple sclerosis (MS), this study aimed to examine the direct and indirect association between fall history and depressive symptoms. METHODS: One hu... (Source: SafetyLit)
Source: SafetyLit - February 19, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

'Adaptive' Yoga Opens This Practice to Everyone
Adaptive yoga, is designed to open up the practice to everyone -- including people with movement-limiting conditions like multiple sclerosis, arthritis, or spinal cord injuries. (Source: WebMD Health)
Source: WebMD Health - February 18, 2021 Category: Consumer Health News Source Type: news

Bringing innovation to rare disease patients in Europe
Why is Biogen focusing on rare diseases?  About 6,000 different rare diseases have been identified to date and these are estimated to affect 30 million people across Europe. It is essential that we collaborate across the medical community, industry, and governments to develop new therapies, explore new technologies and ensure equitable access to treatment. We must innovate across every aspect of treatment to transform the lives of people in these underserved communities.  At Biogen, we have shown that pioneering in neuroscience can change the course of treatment for certain rare diseases. We have transformed the ...
Source: EyeForPharma - February 17, 2021 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news

Reproducibility and convergent validity of the sitting-rising test in people with multiple sclerosis - Greenberg T, Soll R, Dolev M, Kalron A.
OBJECTIVE: To evaluate the test-retest reproducibility and convergent validity of the Sitting-Rising Test (SRT) in people with multiple sclerosis (PwMS). DESIGN: Observational study comprising a test-retest design. SETTING: Multiple Sclerosis Cente... (Source: SafetyLit)
Source: SafetyLit - February 15, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Clinical predictors of driving simulator performance in drivers with multiple sclerosis - Krasniuk S, Classen S, Morrow SA, Alvarez L, He W, Srinivasan S, Monahan M.
BACKGROUND: Drivers with multiple sclerosis (MS) may experience visual-cognitive impairment that affects their fitness to drive. Due to limitations associated with the on-road assessment, an alternative assessment that measures driving performance is warra... (Source: SafetyLit)
Source: SafetyLit - February 13, 2021 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

Can Gut Parasites Slow the Aging Process? Can Gut Parasites Slow the Aging Process?
A decline in these microbes in developed nations has been linked to inflammatory illnesses such as asthma, atopic eczema, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and T1D.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 9, 2021 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Occupational therapy interventions in adults with multiple sclerosis or amyotrophic lateral sclerosis: a scoping review - De-Bernardi-Ojuel L, Torres-Collado L, Garc ía-de-la-Hera M.
This scoping review aims to describe occupational therapy interventions carried out with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) patients in occupational therapy. A peer review of the literature was conducted in different databases:... (Source: SafetyLit)
Source: SafetyLit - February 8, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Can powered exoskeletons improve gait and balance in multiple sclerosis? A retrospective study - Russo M, Maggio MG, Naro A, Portaro S, Porcari B, Balletta T, De Luca R, Raciti L, Calabr ò RS.
Multiple sclerosis (MS) is a progressive neurologic disorder that can profoundly influence mobility, independence and quality of life. Gait dysfunction in MS is common, resulting in an increased risk of losing walking ability. Robotic exoskeletons have bee... (Source: SafetyLit)
Source: SafetyLit - February 6, 2021 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news

Elective C-Sections, Induced Delivery Up for Moms With MS
THURSDAY, Feb. 4, 2021 -- Women with multiple sclerosis (MS) have no significant differences in severe adverse perinatal outcomes compared with the general population, but they do have an increased prevalence of elective cesarean section, induced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news

Roche reports solid results in 2020
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “Roche continues to make important contributions to fighting the COVID-19 pandemic. We developed in record time a comprehensive portfolio of diagnostic solutions and entered new partnerships to develop and produce effective COVID-19 medicines. The deman d for our new medicines which benefit people living with serious conditions, such as cancer, multiple sclerosis, haemophilia and spinal muscular atrophy, remains high. Based on our rejuvenated portfolio and the significant progress made in developing our product pipeline, Roche is strongly positi...
Source: Roche Media News - February 4, 2021 Category: Pharmaceuticals Source Type: news

Roche reports solid results in 2020
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “Roche continues to make important contributions to fighting the COVID-19 pandemic. We developed in record time a comprehensive portfolio of diagnostic solutions and entered new partnerships to develop and produce effective COVID-19 medicines. The deman d for our new medicines which benefit people living with serious conditions, such as cancer, multiple sclerosis, haemophilia and spinal muscular atrophy, remains high. Based on our rejuvenated portfolio and the significant progress made in developing our product pipeline, Roche is strongly positi...
Source: Roche Investor Update - February 4, 2021 Category: Pharmaceuticals Source Type: news

MS Doesn't Put Women at Higher Risk During Pregnancy
WEDNESDAY, Feb. 3, 2021 -- In a finding that should reassure women with multiple sclerosis (MS) who want to have a baby, new research suggests the disease doesn't raise the risk of pregnancy complications. " Women with multiple sclerosis may be... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 3, 2021 Category: General Medicine Source Type: news